News
Valbiotis Announces the Publication of the First Scientific Papers on TOTUM•63 in Three International Journals, Elucidating Its Multitarget Mode of Action
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic diseases
GenSight Biologics Announces Publication of Indirect Comparison Showing Treatment Effect of LUMEVOQ® versus Natural History in Frontiers in Neurology
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
GenSight Biologics to Host a Key Opinion Leader Webinar on the Nature Medicine Case Report: Visual Recovery after GS030 Optogenetic Treatment
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
Sensorion to Attend Two Conferences in June 2021
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Valbiotis erhält einen Innovationsförderkredit über 1,25 Millionen Euro von Bpifrance
Valbiotis (FR0013254851 – ALVAL, PEA/SME-fähig) (Paris:ALVAL), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Vorbeugung und Bekämpfung von
Valbiotis Granted a €1.25 Million Innovation Support Loan by Bpifrance
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic
MND : New major snowmaking project in Russia
MND, the French industrial group specializing in ropeway mobility, snowmaking systems, mountain safety and sensational leisure infrastructures, has been selected in an international tender to supply
METABOLIC EXPLORER : METEX provides an update on the situation at its Amiens plant.
METEX provides an update on the situation at its Amiens plant
Clermont-Ferrand, May 26, 2021 – (FR0004177046 METEX), METabolic EXplorer (METEX), specialized in the design, development and
DOLFINES (EX DIETSWELL) : DOILFINES enters into exclusive discussions for the buyout of 8.2 France
PRESS RELEASE Montigny le Bretonneux, May 24, 2021
DOLFINES enters into exclusive discussions for the buyout of 8.2 France:
first step of the Cash&Value21/25 Renewable
Valbiotis erhält Patent für seinen Wirkstoff TOTUM•63 in China, einem Markt mit großem Potential bei der Vorbeugung von Typ-2-Diabetes und Stoffwechselkrankheiten
Valbiotis (FR0013254851 – ALVAL, PEA/SME-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von
MND : 2020/2021 half-year results - Outlook for second-half 2020/2021
2020/2021 half-year results
Solid resilience in activity, decline limited to -5%
Operational break-even target (adjusted EBITDA) achieved in H1
Outlook for second-half 2020/2021
Sustained business
Valbiotis Obtains Patent for Its Active Substance TOTUM•63 in China, a Large Potential Market for the Prevention of Type 2 Diabetes and Metabolic Diseases
Regulatory News:
Valbiotis (FR0013254851 - ALVAL, eligible for the PEA / SME), a Research and Development company committed to scientific innovation for preventing and combating metabolic
AGROGENERATION : General Meeting to be held behind closes doors on June 24, 2021
Paris, May 19th, 2021
Amid the ongoing COVID-19 epidemic and in line with government measures to slow the spread of the virus and the provisions of Decree No. 2021-255 of March 9, 2021, the
GenSight Biologics Appoints Country Leads for France, Germany and the UK in Preparations for LUMEVOQ® Commercial Launch
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Sensorion Publishes Results of Combined General Meeting Resolutions
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
ENERTIME SUBMITS A NEW APPLICATION TO ADEME FOR AN ORC PROJECT IN FRANCE AND UPDATES ON THE PROGRESS OF ITS STRATEGY
ENERTIME (FR0011915339 - ALENE), a French “CleanTech” company serving industrial energy efficiency and geothermal energy generation, announces that it has submitted a new application for the
GECI INTERNATIONAL : 2020-21 FULL-YEAR REVENUES
GECI International, the Digital Transformation and Technology Consulting specialist, is reporting pro forma1 full-year revenues of €16.5m, down 26% from the previous year on a comparable basis.
GenSight Biologics Appoints Françoise de Craecker to its Board of Directors
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
PRISMAFLEX INTERNATIONAL : 2020-2021 total sales
2020-2021 financial year affected by the health crisis
2020-2021 total sales: €39.7 million (€37.9 million proforma)
Return to proforma growth in Q4 (+12%)
Significant points
- Printing activity
Sensorion to Attend Three Conferences in May 2021 Including ASGCT to Present a Poster and Co-Chair a Scientific Session
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
GenSight Biologics Announces Publication of Results from the REALITY LHON Natural History Study in the Journal Eye
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210502005042/en/
Figure 1. Evolution of BCVA in ND4-LHON patients
Sensorion Hosting Key Opinion Leader Webinar with Dr. Thomas Lenarz on the GJB2 Gene Related Hearing Loss on May 10, 2021
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
GROUPE LDLC : 2020/2021 REVENUES UP 46.8% TO EUR 724.1M
- Q4 REVENUES UP 50.7% TO €182.0M (UP 31.1% AT CONSTANT CONSOLIDATION SCOPE)
- SUSTAINED ROBUST GROWTH IN ALL BUSINESSES
- FULL-YEAR BTOC REVENUES UP 62.6% TO €526.2M (UP 30.0% AT CONSTANT
AGROGENERATION : 2020 annual results
-
Successful turnaround, supported by good production performance, commodity price increases, and management cost cutting
- Remarkable EBITDA of €19.5 million vs (€1.2) million in 2019
- Positive
DOLFINES (EX DIETSWELL) : Full Year 2020 Results
PRESS RELEASE Montigny le Bretonneux, April 26, 2021
FY 2020 RESULTS
- 2020 results marked by the impact of the health pandemic on the Global Oil and Gas business